Emerging drugs for dementia with Lewy bodies: A review of Phase II & amp; III trials
Expert Opin Emerg Drugs. 2023 Aug 2. doi: 10.1080/14728214.2023.2244425. Online ahead of print.ABSTRACTINTRODUCTION: Despite faster cognitive decline and greater negative impact on patients and family caregivers, drug development efforts in Dementia with Lewy Bodies (DLB) fall behind those for Alzheimer's Disease (AD). Current off-label drug DLB treatment options are limited to symptomatic agents developed to address cognitive deficits in AD, motor deficits in Parkinson's Disease, or behavioral symptoms in psychiatric disease. Aided by recent improvements in DLB diagnosis, a new focus on the development of disease-modifyin...
Source: Expert Opinion on Emerging Drugs - August 2, 2023 Category: Drugs & Pharmacology Authors: Magdalena I Tolea Reem Ezzeddine Simone Camacho James E Galvin Source Type: research
Status of current trials and potential future trials with sparsentan
Expert Opin Emerg Drugs. 2023 Jul 23:1-3. doi: 10.1080/14728214.2023.2239151. Online ahead of print.NO ABSTRACTPMID:37466432 | DOI:10.1080/14728214.2023.2239151 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - July 19, 2023 Category: Drugs & Pharmacology Authors: Howard Trachtman Radko Komers Jula Inrig Source Type: research
